warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
Seattle Genetics SGN19A-003: A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory dif
Brief Description  
Primary: Compare CR in patients with relapsed/ refractory DLBCL who are candidates for AASCT treated with Denituzumab Mafodotin + RICE vs RICE. Secondary: Evaluate Safety of denetuzumab mafodotin, Compare PFS between study arms, Compare OS between study arms, Compare proportion of patients able to adequately mobilize PBSC between study arms, Compare proportion of patients able to receive ASCT following study treatment, Compare other measure of antitumor activity between study arms
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Hodgkin's Lymphoma
Status  
OPEN
Start Date  
06/30/2016
IRB Number  
00016462
Principal Investigator  
Ghosh, Nilanjan
Contact Name  
Leslie Walker

For More Information, Contact  Leslie  , Walker
Phone:  980-442-2033 Fax:    
Email:  Leslie.Walker@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close